Clinical Trial Update: Alemtuzumab and Low-Dose Cyclosporine in Treating Patients With Severe Aplastic Anemia or Acquired Marrow Failure [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating alemtuzumab with low-dose cyclosporine in patients with severe aplastic anemia or acquired marrow failure.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aplastic Anemia
• Bone Marrow Failure

Drugs mentioned

• Alemtuzumab (Alemtuzumab)
• CYCLOSPORINE (cyclosporine)

Snippet

Sponsor: Federico II University | Conditions: Nonmalignant Neoplasm | Phase 2 | Status: UNKNOWN